An FDA advisory panel voted that a long-acting, injectable
form of Eli Lilly's best-selling
drug, the antipsychotic olanzapine, is safe enough for use in
some patients with schizophrenia. But panel members shared concerns raised by
the FDA that Zyprexa LAI was
associated with excessive sedation.